Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis

IMPORTANCE: In patients with multiple sclerosis (MS), factors associated with severe COVID-19 include anti-CD20 therapies and neurologic disability, but it is still unclear whether these 2 variables are independently associated with severe COVID-19 or whether the association depends on MS clinical c...

Descripción completa

Detalles Bibliográficos
Autores principales: Januel, Edouard, Hajage, David, Labauge, Pierre, Maillart, Elisabeth, De Sèze, Jérome, Zephir, Hélène, Pelletier, Jean, Guilloton, Laurent, Bensa, Caroline, Heinzlef, Olivier, Casez, Olivier, Biotti, Damien, Bourre, Bertrand, Vukusic, Sandra, Maurousset, Aude, Berger, Eric, Laplaud, David, Lebrun-Frénay, Christine, Dubessy, Anne-Laure, Branger, Pierre, Thouvenot, Eric, Clavelou, Pierre, Sellal, François, Manchon, Eric, Moreau, Thibault, Papeix, Caroline, Tubach, Florence, Louapre, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290250/
https://www.ncbi.nlm.nih.gov/pubmed/37351881
http://dx.doi.org/10.1001/jamanetworkopen.2023.19766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290250/
https://www.ncbi.nlm.nih.gov/pubmed/37351881
http://dx.doi.org/10.1001/jamanetworkopen.2023.19766

Ejemplares similares